Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renaud Felten

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Expert Opinion on Biological Therapy|August 17, 2024
IL-17 inhibitors in axial spondyloarthritis. An overviewEric Toussirot, Renaud Felten
Drugs & Aging|October 30, 2023
Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older PatientsRenaud Felten, Eric Toussirot
Rheumatology and Therapy|March 13, 2022
Responding to and Driving Change in Rheumatology: Report from the 12th International Immunology Summit 2021Renaud Felten, Nicolas Rosine
Joint Bone Spine|July 11, 2026
Evolution of direct and indirect costs of rheumatoid arthritis and related conditions in France: a 2015-2023 nation-wide population-based studyMathilde Richard, Renaud Felten, Laurent Arnaud
Infectious Diseases and Therapy|September 26, 2022
Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the PandemicMarc Scherlinger, Cédric Lemogne, Renaud Felten, et al.
Therapeutic Advances in Musculoskeletal Disease|April 25, 2022
Is there still a place for methotrexate in severe psoriatic arthritis?Renaud Felten, Grégoire Lambert De Cursay, Eric Lespessailles
Therapeutic Advances in Musculoskeletal Disease|February 21, 2022
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledgeAlina Dima, Ciprian Jurcut, François Chasset, et al.
Therapeutic Advances in Musculoskeletal Disease|January 6, 2021
Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysisArthur Petitdemange, Julien Blaess, Jean Sibilia, et al.
Drug Design, Development and Therapy|June 14, 2019
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to dateRenaud Felten, Florence Scher, Flora Sagez, et al.
Therapeutic Advances in Musculoskeletal Disease|May 28, 2021
Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international surveyArthur Petitdemange, Renaud Felten, Jean Sibilia, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Expert Opinion on Biological Therapy|August 17, 2024
IL-17 inhibitors in axial spondyloarthritis. An overviewEric Toussirot, Renaud Felten
Drugs & Aging|October 30, 2023
Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older PatientsRenaud Felten, Eric Toussirot
Rheumatology and Therapy|March 13, 2022
Responding to and Driving Change in Rheumatology: Report from the 12th International Immunology Summit 2021Renaud Felten, Nicolas Rosine
Joint Bone Spine|July 11, 2026
Evolution of direct and indirect costs of rheumatoid arthritis and related conditions in France: a 2015-2023 nation-wide population-based studyMathilde Richard, Renaud Felten, Laurent Arnaud
Infectious Diseases and Therapy|September 26, 2022
Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the PandemicMarc Scherlinger, Cédric Lemogne, Renaud Felten, et al.
Therapeutic Advances in Musculoskeletal Disease|April 25, 2022
Is there still a place for methotrexate in severe psoriatic arthritis?Renaud Felten, Grégoire Lambert De Cursay, Eric Lespessailles
Therapeutic Advances in Musculoskeletal Disease|February 21, 2022
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledgeAlina Dima, Ciprian Jurcut, François Chasset, et al.
Therapeutic Advances in Musculoskeletal Disease|January 6, 2021
Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysisArthur Petitdemange, Julien Blaess, Jean Sibilia, et al.
Drug Design, Development and Therapy|June 14, 2019
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to dateRenaud Felten, Florence Scher, Flora Sagez, et al.
Therapeutic Advances in Musculoskeletal Disease|May 28, 2021
Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international surveyArthur Petitdemange, Renaud Felten, Jean Sibilia, et al.
Pageof 7